ABSTRACT
Suppose you are conducting a trial of standard fractionation RT vs. hyperfractionated RT in lung cancer and the data are looking interesting halfway through the trial. You decide to do a test and find the logrank test of survival has p-value 0.05. Is it legitimate to stop the trial at this point and conclude that hyperfractionation is superior to standard fractionation?
